44 results
S-1/A
EX-3.1
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all … . Each of the following events shall be considered a “Deemed Liquidation Event” unless (i) the holders of at least a majority of the outstanding
S-1/A
EX-3.3
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
) the Chairman, if there be one, or (ii) the President, or (iii) the Secretary and shall be called by any such officer at the request in writing of a majority … or by the Certificate of Incorporation, the holders of a majority of the capital stock issued and outstanding and entitled to vote thereat, present
S-1/A
EX-3.2
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power … of a majority of the Directors then in office, and special meetings of stockholders may not be called by any other person or persons. Only those matters set
10-K
2021 FY
EX-4.2
CADL
Candel Therapeutics Inc
29 Mar 22
Annual report
8:46am
in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum … of stockholders. Our amended and restated certificate of incorporation and bylaws provide that only a majority of the members of our board of directors
8-K
EX-3.2
CADL
Candel Therapeutics Inc
30 Jul 21
Departure of Directors or Certain Officers
12:00am
by the affirmative vote of a majority of the Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled … be amended and/or restated, the “Certificate”) or these Bylaws, is entitled to such notice.
SECTION 5. Quorum. A majority of the shares entitled to vote
8-K
EX-3.1
yts0us5tr5bbu6 xe
30 Jul 21
Departure of Directors or Certain Officers
12:00am
S-1
EX-4.2
jajt0defgs1z2 75ff
25 Jun 21
IPO registration
5:28pm
S-1/A
EX-3.4
vcj4730u7qxmei9l
16 Jul 21
IPO registration (amended)
6:07am
S-3
EX-4.9
lpu2u 8szfhf
5 Aug 22
Shelf registration
5:08pm
S-3
EX-4.8
cguw2 jp3
5 Aug 22
Shelf registration
5:08pm
S-3
3jnszo8ofyd7w
5 Aug 22
Shelf registration
5:08pm
S-1/A
EX-10.6
ykvjwzq7
16 Jul 21
IPO registration (amended)
6:07am
DEF 14A
p5stpz pkp
2 Sep 22
Definitive proxy
8:30am
8-K
EX-99.1
q2lck71j
26 May 22
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
5:36pm
S-1/A
EX-4.4
vgqi5y2yn12n ikm5xf
16 Jul 21
IPO registration (amended)
6:07am
8-K
EX-99.1
n9q c0wn0is
6 Dec 22
Regulation FD Disclosure
8:01am